First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor
Mené sur 41 patients atteints d’une tumeur de stade avancé, cet essai de phase I évalue la dose maximale tolérée et l’efficacité, du point de vue du taux de réponse, de E7449, un inhibiteur de PARP 1/2 et de tankyrase 1/2
Background : This phase 1 study examined the safety, maximum-tolerated dose (MTD) and antitumour activity of E7449, a novel PARP 1/2 and tankyrase 1/2 inhibitor. Methods : E7449 was orally administered once daily in 28-day cycles to patients with advanced solid tumours (50–800-mg doses). Archival tumour samples from consenting patients were evaluated for the expression of 414 genes in a biomarker panel (2X-121 drug-response predictor [DRP]) found to be predictive of the response to E7449 in cell lines.Results : Forty-one patients were enrolled (13 pancreatic, 5 ovarian, 4 each with breast, lung or colorectal cancer and 11 with other tumour types). The most common grade ?3 treatment-related adverse event was fatigue (n=7, 17.1%). Five patients experienced a dose-limiting toxicity (fatigue, n=4, 800mg; anaphylaxis, n=1, 600mg) for an MTD of 600mg. E7449 exhibited antitumour activity in solid tumours, including 2 partial responses (PRs), and stable disease (SD) in 13 patients, which was durable (>23 weeks) for 8 patients. In 13 patients, the 2X-121 DRP identified those achieving PR and durable SD. E7449 showed good tolerability, promising antitumour activity and significant concentration-dependent PARP inhibition following 50–800-mg oral dosing. Conclusion : The results support further clinical investigation of E7449 and its associated biomarker 2X-121 DRP.